GlassScriptPhysician profile
Spencer Moore
NPI 1710535778
$8,858.45
in general payments reported to CMS, 2019-2025
15 companies · $2,720 in 2025
The $2,720 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $644 · 2021: $939 · 2022: $2,254 · 2023: $1,026 · 2024: $692 · 2025: $2,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,578 · Consulting Fee: $1,740 · Entertainment: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,578.25 |
| Consulting Fee | $1,740.20 |
| Entertainment | $120.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $5,904.05 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,291.78 | 2020-2025 | Dailies Total1, Precision7, Precision 1 |
| Coopervision INC. | $276.93 | 2020-2025 | Misight Contact Lens |
| Carl Zeiss Meditec USA, INC. | $268.54 | 2023 | Humphrey Hfa, Cirrus Hd-Oct |
| Optos, INC. | $215.20 | 2022-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Lumenis Be INC | $201.59 | 2022 | |
| Bausch & Lomb Americas INC. | $175.65 | 2022-2024 | Infuse |
| Allergan, INC. | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $119.85 | 2019 | |
| Rxsight INC | $88.24 | 2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Sun Pharmaceutical Industries INC. | $48.32 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.92 | 2020 | |
| Lumenis, INC | $38.97 | 2021 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $19.61 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.